Literature DB >> 33587330

Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.

Katherine D Lynch1, Michelle L Montonye1, Dan-Dan Tian1, Tarana Arman1, Victoria O Oyanna1, Baron J Bechtold1, Tyler N Graf2, Nicholas H Oberlies2, Mary F Paine1, John D Clarke1.   

Abstract

Silybum marianum (L.) Gaertn. (Asteraceae), commonly known as milk thistle, is a botanical natural product used to self-treat multiple diseases such as Type 2 diabetes mellitus and nonalcoholic steatohepatitis (NASH). An extract from milk thistle seeds (achenes), termed silymarin, is comprised primarily of several flavonolignans. Systemic concentrations of these flavonolignans can influence the potential biologic effects of silymarin and the risk for pharmacokinetic silymarin-drug interactions. The aims of this research were to determine the roles of organic anion transporting polypeptides (OATPs/Oatps) in silymarin flavonolignan disposition and in pharmacokinetic silymarin-drug interactions. The seven major flavonolignans from silymarin were determined to be substrates for OATP1B1, OATP1B3, and OATP2B1. Sprague Dawley rats were fed either a control diet or a NASH-inducing diet and administered pitavastatin (OATP/Oatp probe substrate), followed by silymarin via oral gavage. Decreased protein expression of Oatp1b2 and Oatp1a4 in NASH animals increased flavonolignan area under the plasma concentration-time curve (AUC) and maximum plasma concentration. The combination of silymarin inhibition of Oatps and NASH-associated decrease in Oatp expression caused an additive increase in plasma pitavastatin AUC in the animals. These data indicate that OATPs/Oatps contribute to flavonolignan cellular uptake and mediate the interaction between silymarin and NASH on pitavastatin systemic exposure.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  flavonolignans; nonalcoholic steatohepatitis; organic anion transporting polypeptide; pharmacokinetics; pitavastatin; silymarin

Mesh:

Substances:

Year:  2021        PMID: 33587330      PMCID: PMC8217340          DOI: 10.1002/ptr.7049

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   6.388


  47 in total

1.  A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.

Authors:  Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Katherine D Lynch; Bruno Hagenbuch; Mary F Paine; John D Clarke
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

2.  Dietary Silymarin Supplementation Alleviates Zearalenone-Induced Hepatotoxicity and Reproductive Toxicity in Rats.

Authors:  Xin Gao; Zhuo-Hui Xiao; Meng Liu; Ni-Ya Zhang; Mahmoud Mohamed Khalil; Chang-Qin Gu; De-Sheng Qi; Lv-Hui Sun
Journal:  J Nutr       Date:  2018-08-01       Impact factor: 4.798

3.  Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-01-02       Impact factor: 3.922

4.  Evaluation of Organic Anion Transporter 1A2-knock-in Mice as a Model of Human Blood-brain Barrier.

Authors:  Yamato Sano; Tadahaya Mizuno; Tatsuki Mochizuki; Yasuo Uchida; Mina Umetsu; Tetsuya Terasaki; Hiroyuki Kusuhara
Journal:  Drug Metab Dispos       Date:  2018-08-28       Impact factor: 3.922

Review 5.  Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Authors:  K M Hillgren; D Keppler; A A Zur; K M Giacomini; B Stieger; C E Cass; L Zhang
Journal:  Clin Pharmacol Ther       Date:  2013-04-08       Impact factor: 6.875

6.  A validated UHPLC-tandem mass spectrometry method for quantitative analysis of flavonolignans in milk thistle (Silybum marianum) extracts.

Authors:  Tyler N Graf; Nadja B Cech; Stephen J Polyak; Nicholas H Oberlies
Journal:  J Pharm Biomed Anal       Date:  2016-04-22       Impact factor: 3.935

7.  Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Authors:  Sonia R Miranda; Jin Kyung Lee; Kim L R Brouwer; Zhiming Wen; Philip C Smith; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-08-07       Impact factor: 3.922

8.  Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention.

Authors:  Tyler N Graf; Mansukh C Wani; Rajesh Agarwal; David J Kroll; Nicholas H Oberlies
Journal:  Planta Med       Date:  2007-10-18       Impact factor: 3.352

9.  Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Authors:  Michael W Fried; Victor J Navarro; Nezam Afdhal; Steven H Belle; Abdus S Wahed; Roy L Hawke; Edward Doo; Catherine M Meyers; K Rajender Reddy
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

10.  Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Authors:  John D Clarke; Petr Novak; April D Lake; Rhiannon N Hardwick; Nathan J Cherrington
Journal:  Liver Int       Date:  2017-02-07       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.